• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Bioretec

0.02 EUR

-1.90 %

1,794 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-1.90 %
+51.47 %
+49.92 %
-62.65 %
-66.65 %
-87.41 %
-90.45 %
-
-92.04 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
27.64M EUR
Turnover
27.12K EUR
P/E (adj.) (26e)
-3.6
EV/EBIT (adj.) (26e)
-2.95
P/B (26e)
1.84
EV/S (26e)
4.07
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
0.02 EUR
Updated
17.05.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.05.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Bioretec announces that its CEO Sarah van Hellenberg Hubar-Fisher has purchased a total of 1,660,000 shares of the company at a price of 0.02258 euros per share. She purchased the shares for a total of 37,482.20 euros. According to information published by the company at the end ...
6/4/2026, 12:00 PM
by Index
16
Stock Exchange Release Bioretec Ltd - Managers’ Transactions - Jordy Winters Bioretec Ltd Company Release 2 June 2026 at 1:25 p.m. EEST Person subject to the notification requirement Name: Jordy Winters Position: Other senior management Nature of the transaction: ACQUISITION Volume...
6/2/2026, 10:39 AM
by Index
14
CFO Paavola also bought a stack of shares some time ago. Quite a few insiders have been buying.
6/4/2026, 12:54 PM
by Pertti
10
Since biodegradable screws eliminate the need for removal surgery, it can be assumed that the number of complications will decrease, based on the premise that surgeries in general always carry a risk of complications. The US market operates primarily on a fee-for-service basis as...
5/22/2026, 12:59 PM
by Matti
8
A 200 million euro balance sheet and a 100% equity ratio. His previous company, Picosun, was sold for hundreds of millions, which is the source of the company’s significant wealth.
5/21/2026, 7:40 AM
by Roni
7
So at least within the company, faith is strong. It’s a bit reassuring
6/5/2026, 6:42 AM
by Kahvifreak
4
Yeah, I have to open my mouth as well, since I’ve been following this since the early days of the FDA clearance application. The offering ended up being quite successful and the share price has started a slight upward trend. Personally, I have very mixed feelings about the share ...
5/23/2026, 10:59 PM
by Valle
3
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.8
2026

Interim report Q2'26

12.11
2026

Business review Q3'26

Regulatory press release6/4/2026, 11:25 AM

Bioretec Ltd - Manager's transactions - van Hellenberg Hubar-Fisher

Bioretec
Regulatory press release6/2/2026, 10:25 AM

Bioretec Ltd - Manager's transactions - Jordy Winters

Bioretec
Bioretec seeks additional savings through change negotiations
Analyst Comment6/2/2026, 7:18 AM by
Antti Siltanen

Bioretec seeks additional savings through change negotiations

The company is seeking additional savings of 0.2 MEUR, as production capacity is still too high relative to demand.

Bioretec

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/1/2026, 4:05 PM

The Board of Directors of Bioretec Ltd resolved on a new stock option plan

Bioretec
Regulatory press release6/1/2026, 4:00 PM

Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency

Bioretec
Regulatory press release5/18/2026, 10:45 AM

Bioretec Ltd - Managers' transactions - Paavola

Bioretec
Bioretec Q1'26: The beginning of the year offered positive signs7:09
Video5/18/2026, 7:45 AM by
Antti Siltanen

Bioretec Q1'26: The beginning of the year offered positive signs

Bioretec's Q1 earnings positively surprised in terms of revenue and profit, particularly due to growth in the US and European markets.

Bioretec
Bioretec Q1'26: Early signs of growth emerging
Research5/18/2026, 7:25 AM by
Antti Siltanen

Bioretec Q1'26: Early signs of growth emerging

Bioretec's start to the year offered a positive surprise.

Bioretec
Regulatory press release5/15/2026, 6:00 AM

Bioretec Ltd's business review Q1 2026: Early Traction from Renewed Strategy

Bioretec
Regulatory press release5/13/2026, 11:00 AM

Bioretec clarifies its 2026-2028 financial target regarding the sales margin

Bioretec
Bioretec Q1'26 preview: Initiating RemeOs sales in Europe
Analyst Comment5/12/2026, 6:46 AM by
Antti Siltanen

Bioretec Q1'26 preview: Initiating RemeOs sales in Europe

In the report, our attention is drawn to the development of RemeOs sales in Europe and the United States.

Bioretec
Regulatory press release5/8/2026, 5:40 PM

Bioretec Ltd's resolutions of the constitutive meeting of the Board of Directors

Bioretec
Regulatory press release5/8/2026, 11:45 AM

Bioretec Ltd's resolutions of the Annual General Meeting

Bioretec
Regulatory press release4/29/2026, 1:40 PM

Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö)

Bioretec
Bioretec: Successful share issue to drive new growth
Research4/29/2026, 7:17 AM by
Antti Siltanen

Bioretec: Successful share issue to drive new growth

The share issue secures funding at least until mid-2027.

Bioretec
Regulatory press release4/28/2026, 1:55 PM

Bioretec Ltd - Manager's transactions - Stephen Industries Inc Oy

Bioretec
Regulatory press release4/28/2026, 12:55 PM

Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Kustaa Poutiainen)

Bioretec
Regulatory press release4/28/2026, 10:40 AM

Bioretec Ltd adjusts the terms and conditions of its stock option programs due to the completed rights issue

Bioretec
Regulatory press release4/28/2026, 10:10 AM

New shares of Bioretec Ltd registered with the trade register

Bioretec
Regulatory press release4/27/2026, 1:00 PM

Bioretec Ltd - Manager's transactions - Paavola

Bioretec